87.3 🩺 內科專科考前版

87.3.0.1 📌 䞀頁重點

  • 22E: atezo+bev IMbrave150, durva+treme HIMALAYA, durvalumab + chemo cholangio TOPAZ-1, pemigatinib FGFR2, ivosidenib IDH1
  • Taiwan: HBV/HCV → HCC; 嬰兒疫苗 1984; 健保 DAA HCV cure 倧幅枛少 HCC

87.3.0.2 🌟 Pearls (10)

  1. IMbrave150: atezo + bev > sorafenib (HCC)
  2. HIMALAYA: durva + treme dual immunotherapy
  3. TOPAZ-1: gem-cis + durvalumab cholangio
  4. Pemigatinib for FGFR2 fusion iCCA (FIGHT-202)
  5. Ivosidenib for IDH1 iCCA (ClarIDHy)
  6. Lenvatinib + pembrolizumab trial combo HCC
  7. Y-90 TARE alternative to TACE
  8. Liver transplant downstaging for HCC outside Milan
  9. Bridge therapy to transplant
  10. Cholangiocarcinoma multi-omic profiling (NGS + IHC)

87.3.0.3 📍 Taiwan

  • HCC: 男性死亡率 #2
  • 健保 DAA HCV all-line
  • 健保 antiviral HBV (entecavir, tenofovir)
  • 健保 sorafenib, lenvatinib, regorafenib, ramucirumab, atezo+bev (條件)
  • 健保 cabozantinib (條件)
  • 健保 transplant HCC Milan
  • TACE/TARE 廣泛
  • 健保 pemigatinib / ivosidenib 限制

87.3.0.4 🎓 內專重點

  1. HCC risk + surveillance (台灣特殊)
  2. LI-RADS + BCLC
  3. Milan + transplant + bridging
  4. 1st line atezo+bev, HIMALAYA dual immuno
  5. Cholangio targets FGFR2/IDH1/HER2/MSI
  6. TOPAZ-1 gem-cis + durvalumab
  7. GB cancer adjuvant (BILCAP)

⚠ AI 草皿。